Tyrosine Kinases as Targets for Cancer Therapy
Top Cited Papers
- 14 July 2005
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (2) , 172-187
- https://doi.org/10.1056/nejmra044389
Abstract
Tyrosine kinases, enzymes that catalyze the transfer of phosphate from ATP to tyrosine residues in polypeptides, are ubiquitous, numerous, and of considerable clinical interest because they participate in the development of cancer and have become choice targets for therapeutic intervention. This comprehensive review discusses the molecular and clinical aspects of tyrosine kinases.Keywords
This publication has 110 references indexed in Scilit:
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002